natgillin/translations-raw huggingface dataset:
The composition of claim 3 or 4, further comprising a second therapeutic agent useful in the treatment or prevention of a disease or condition selected from emotional lability; pseudobulbar affect; autism; neurological disorders; neurodegenerative diseases; brain injury; disturbances of consciousness disorders; cardiovascular diseases; glaucoma; tardive dyskinesia; diabetic neuropathy; retinopathic diseases; diseases or disorders caused by homocysteine-induced apoptosis; diseases or disorders caused by elevated levels of homocysteine; chronic pain; intractable pain; neuropathic pain; sympathetically mediated pain; pain associated with gastrointestinal dysfunction; epileptic seizures; tinnitus; sexual dysfunction; intractable coughing; dermatitis; addiction disorders; Rett syndrome (RTT); voice disorders due to uncontrolled laryngeal muscle spasms; methotrexate neurotoxicity; and fatigue caused by cancer. 
Smjesa prema zahtjevu 3 ili 4, ili zahtjevima 5-8 kada ovise o zahtjevu 3 ili 4, koja dalje sadrži drugo terapijsko sredstvo korisno u liječenju ili prevenciji bolesti ili stanja izabranih između; emocionalna nestabilnost; pseudobulbarni afekt; autizam; neurološki poremećaji; neurodegenerativne bolesti; ozljeda mozga; poremećaji svijesti; kardiovaskularne bolesti; glaukom; tardivna diskimezija; dijabetička neuropatija; retinopatijske bolesti; bolesti ili poremećaji uzrokovani apoptozom koja je inducirana homocisteinom; bolesti ili poremećaji uzrokovani povišenim razinama homocisteina; kronična bol; intraktabilna bol; neuropatska bol; bol posredovana simpatikusom; bol povezana s disfunkcijom probavnog sustava; cpiloptički napadaji; tinitus; seksualna disfunkcija; intraktabilni kašalj; dermatitis; poremećaji ovisnosti; Rettov sindrom (RTT); poremećaji glasa uslijed nekontroliranog grčenja mišića larinksa; neurotoksičnost metotreksata; i umor uzrokovan rakom.
Wood impregnated with the solution for wood preservative according to the present invention is resistant against termites (Kalotermes flavicolis) as well. 
Drvo impregnirano otopinom za konzerviranje drva prema ovom izumu je otporno i na termite (Kalotermes flavicolis).
represents a heterocyclic group which may be substituted, an alkoxycarbonyl or heterocyclic carbonyl group which may be substituted, or a carboxyl group which may be protected; 
R* predstavlja heterocikličku skupinu koja može biti supstituirana, alkoksikarbonilnu ili heterocikličku karbonilnu skupinu koja može biti supstituirana ili karboksilnu skupinu koja može biti zaštićena;
The invention also encompasses intermediates useful for making the pyrimidone compounds. 
Izum također obuhvaća intermedijere korisne za pripremu spojeva pirimidinona.
The expansion joint according to claim 3, wherein the first vertically oriented corrugated plate of the upper portion and the first vertically oriented corrugated plate of the lower portion are in substantially the same lateral plane. 
Kompenzacijski spoj prema bilo kojem od zahtjeva 3 do 5, naznačen time su gornje (4) i prve donje (5) valovite ploče u osnovi u istoj bočnoj ravnini.
The stable two component nanoparticle of claim 1, further comprising at least one of an amphipathic or a hydrophobic molecule. 
Nanočestice prema nekom od prethodnih zahtjeva, koje dodatno sadrže najmanje jednu amfipatičnu ili hidrofobnu molekulu.
comparing the MACERS to a reference MACERS; wherein the MACERS in comparison with the reference MACERS is indicative of the subject's risk of a MACE within one year. 
MACERS = (ST2 T1/ST2 T0 + aln(NP T1), gdje je a težinski faktor; i uspoređujući MACERS s referentnim MACERS-om; gdje je MACERS u usporedbi s referentnim MACERS –om indikativan za rizik osobe za MACE u roku od jedne godine.
oxomorpholinyl, said oxomorpholinyl being unsubstituted or substituted with one or two substituents independently selected from C1-6alkyl and oxazolyl; 
oksomorfolinil, pri čemu je navedeni oksomorfolinil nesupstituiran ili supstituiran s jednim ili dva supstituenta neovisno odabrana iz C1−6alkila i oksazolila;
hydrolyzing the sludge in the hydrolysis reactor (214); 
(d) hidroliziranja mulja u reaktoru za hidrolizu (214);
An isolated nucleic acid molecule comprising a nucleotide sequence encoding the antibody-like binding protein of any one of claims 1-8. 
Izolirana molekula nukleinske kiseline naznačena time da sadrži nukleotidnu sekvencu koja kodira protutijelu sličan vezivni peptid prema bilo kojem od zahtjeva 1, 2, 5 ili 6.
the MCs are obtained from a patient or an allogeneic donor. 
(b) mononuklearne stanicu se dobivene od pacijenta ili alogeneičkog davatelja.
processing the at least one image and identifying particles in the at least one image; 
- < obradu najmanje jedne slike i identifikaciju čestica na slici;
A humanized anti-CD44 antibody, or antigen binding fragment thereof, for use in the treatment of a head and neck squamous cell carcinoma (HNSCC) in a human, wherein said HNSCC is characterized by the expression of CD44 and wherein said humanized antibody comprises a VH domain having the amino acid sequence of SEQ ID NO:9 and a VL domain having the amino acid sequence of SEQ ID NO: 11, or comprises a VH domain having the amino acid sequence of SEQ ID NO:10 and a VL domain having the amino acid sequence of SEQ ID NO: 11. 
Humanizirano protutijelo anti-CD44, ili njegov fragment koji se veže na antigen, koje/koji se upotrebljava za liječenje karcinoma pločastih stanica glave i vrata (HNSCC) kod ljudi, naznačen(o) time, da navedeni HNSCC izražava CD44, pri čemu navedeno humanizirano protutijelo sadrži VH domenu koja ima aminokiselinsku sekvencu SEQ ID NO:9 i VL domenu koja ima aminokiselinsku sekvencu SEQ ID NO: 11, ili sadrži VH domenu koja ima aminokiselinsku sekvencu SEQ ID NO:10 i VL domenu koja ima aminokiselinsku sekvencu SEQ ID NO: 11.
The apparatus of clause 1, further comprising a support for maintaining the height of the channel, the support being disposed within the channel and extending between the separation element and the surface of the void. 
Uređaj prema jednom od patentnih zahtjeva 1 do 9, da nadalje sadrži nosač za zadržavanje visine kanala, nosač je smješten unutar kanala 1 pruža se između elementa odvajanja i površine praznine.
The boom mountable robotic arm of claim 2 wherein said at least one electrically insulated support post is mounted by at least one hinge means to said upper beam assembly. 
Robotska ruka koja se može montirati na krak dizalice prema zahtjevu 1, naznačena time, da je navedeni barem jedan električno izolirani podupirač (42) montiran pomoću zglobnih šarki (60, 94) na navedeni gornji gredni sklop (28).
The method according to claim 1, wherein neratinib is administered in an amount of at least 40 mg per day. 
Kombinacija za uporabu prema zahtjevu 1, gdje se neratinib ili njegova farmaceutski prikladna sol daje u količini od najmanje oko 40 mg.
The single-chain fusion molecule of the present invention comprises additionally three soluble cytokine domains, namely components (i), (iii) and (v). 
(v) treću topljivu citokinsku domenu iz TNF obitelji, pri čemu se fuzijski polipeptid znatno ne agregira 1 pri čemu je topljiva citokinska domena iz TNF obitelji izabrana od topljivih TRAIL domena.
The compound of claim 31, wherein the -(C1-C6) alkyl group is a tert-butyl group or an iso-propyl group. 
Spoj prema zahtjevu 31, naznačen time da (C,-Cg) alkilna skupina je tert-butil skupina ili iso-propil skupina.
A method according to claim 1, further comprising administering one or more other active agents effective in the treatment of multiple sclerosis. 
Sastav za uporabu u skladu s patentnim zahtjevom 1, pri čemu sastav treba primijeniti s jednim ili više drugih aktivnih agenasa učinkovitih u liječenju multiple skleroze.
a plurality of modules (6a, 6b, 6c) are arranged on a support surface (8) of the package (10) such that the modules are in an upright position with the front surfaces of the packages of panels of one row standing on the support surface; 
- veći broj modula (6a, 6b,6c) postavljeni su na potpornu površinu (8) pakiranja (10) tako da se moduli nalaze u okomitom položaju pri čemu prednje površine valjaka ili paketa ploča jednog reda stoje na potpornoj površini;
The radio communication base station according to claim 2, wherein: the first accumulation value, before it undergoes said updating with the TPC command, is set to zero upon said initiation. 
Radio komunikacijski terminalni uređaj sukladno zahtjevu 2, naznačen time da je: prva akumulacijska vrijednost, prije nego što se podvrgne navedenom ažuriranju s naredbom TPC, postavljena na nulu nakon navedenog iniciranja.
TABLE E. Hydrogen coordinates [x 104] and isotropic displacement parameters [Å2 x 103]. 
TABELA E. Koordinate vodika [x 10"] i parametri izotropnog pomaka [A x 107]
at least one sugar and/or at least one sugar alcohol, wherein a major proportion of component (ii) consists of: 
(ii) najmanje jedan šećer i/ili najmanje jedan šećerni alkohol, naznačena time što se glavni dio komponente (ii) sastoji od:
inactivating the Enteroviral particles; and, 
inaktivacije enterovirusnih čestica;
The resultant solution was stirred for 20 hours, and acetonitrile was removed in vacuo. 
Dobivenu otopinu miješa se 20 sati, a acetonitril ukloni u vakuumu.
Nozzle arrangements of the type in question are employed for atomising liquids into very fine droplets by pressing the liquids under a high pressure through a nozzle opening of small cross-section. 
Naprave s mlaznicom spomenute vrste upotrebljavaju se za atomizaciju tekućina u vrlo sitne kapljice protiskivanjem tekućine pod visokim pritiskom kroz otvor mlaznice malog presjeka.
In a particularly preferred embodiment of the invention the N-heterocyclic substances employed are pyrazine derivatives according to formula (I): 
U naročito poželjnom ostvarenju izuma, upotrijebljene N-heterocikličke tvari su derivati pirazina prema formuli(I):
After stirring the reaction mixture under nitrogen atmosphere for 96 hours, it was filtered and concentrated in vacuo. 
Nakon miješanja reakcijske smjese pod atmosferom dušika tijekom 96 sati, ona se filtrira i koncentrira in vacuo.
Headset apparatus according to any preceding claim including locking means arranged to engage with an aforesaid earshell and/or an aforesaid attachment means of the headset to retain the aforesaid attachment means connected to the earshell when the two are fitted together. 
Slušalice prema bilo kojem od prethodnih zahtjeva, naznačene time, da obuhvaćaju zaporno sredstvo raspoređeno da zahvaća s navedenom školjkom za uho i/ili na navedeni priključni uređaj od slušalica, kako bi zadržalo navedeni priključni uređaj u spoju sa školjkom za uho, kada su oboje pričvršćeni zajedno.
Average volume of the disc space of a 
Broj objave europskog patenta:
The compound according to any one of claims 1 to 3, wherein R5 is phenyl optionally substitued by OH, C1-C4 alkyl optionally substituted by one or more OH groups or NH2 groups; C1-C4 alkyl optionally substituted by one or more halogen atoms; C1-C4 alkoxy optionally substituted by one or more OH groups or C1-C4 alkoxy; NR19R21; C(O)OR19; C(O)R19; SR19; OR19; CN; NO2; or halogen; and 
Spoj prema bilo kojem od zahtjeva 1 do 3, naznačen time, da je fenil opcijski supstituiran s OH, C1-C4 alkil opcijski supstituiran s jednomm ili više OH-skupina ili NH2-skupina; C1-C4 alkil opcijski supstituiran s jednim ili više atoma halogena; C1-C4 alkoksi opcijski supstituiran s jednom ili više OH-skupina ili C1-C4 alkoksi; -NR19R21;
The GLYX peptide for use according to any one of claims 1-3, wherein a patient is substantially relieved of at least one symptom within about 1 day to about 14 days after administration of the GLYX peptide. 
GLYX-13 za primjenu u skladu sa bilo kojim od zahtjeva 1 do 4, naznačeno time da se pacijent rezistentan na terapiju definira kao pacijent koji je primio terapiju najmanje dva tipa anti depresivna tretmana prije primjene GLYX-13.
Other suitable materials include inorganic solids such as ceramics, glass, alumina, vermiculite, clays such as bentonite, and the like. 
Drugi pogodni materijali uključuju neorganske čvrste supstance kao što su keramike, staklo, aluminij-oksid, vermikulit, takve gline kao što je bentonit i slične.
Conductivity of the retentate was adjusted after dilution with water to a volume of around 150-200 mL. 
Provodljivost zaostale frakcije bila je podešena nakon razrjeđenja s vodom do volumena oko 150-200 mL.
Calcium salt according to claim 1, wherein the organic or inorganic acid is selected from the group of HCl, HBr, HI, maleic acid and fumaric acid. 
Kalcijeva sol prema zahtjevu 1, naznačena time, da je organska ili anorganska kiselina odabrana iz skupine koju čine HCI, HBr, HI, maleinska kiselina i fumarna kiselina.
It has been well established that improved glycemic control in patients with diabetes (Type I and Type II) is accompanied by decreased microvasclular complications (DCCT and UKPDS). 
Dobro je poznato da poboljšanu kontrolu šećera u krvi kod pacijenata s dijabetesom (tip I i tip II) prate smanjene mikrovasklularne komplikacije (DCCT i UKPDS).
a polypeptide antigen selected from the group consisting of N. meningitidis, S. pneumoniae, Bordetella pertussis, Moraxella catarrhalis, Clostridium tetani, Chorinebacterim diphtheriae, respiratory syncytial virus, polio virus, measles virus, mumps virus, rubella virus, and rotavirus polypeptide antigens; and 
(a) polipeptidni antigen koji se bira iz skupine koju čine polipeptidni antigeni iz bakterija N. meningitidis, S. pneumoniae, Bordetella pertussis, Moraxella catarrhalis, Clostridium tetani, Corynebacterium diphtheriae, respiratornog sincicicijskog virusa, polio virusa, virusa ospica, virusa zaušnjaka, virusa rubeola, te rotavirusa; i
The compound according to claim 1 or 2, wherein when A is a linear or branched alkylene group substituted by a group selected from an optionally substituted aralkyl group and an optionally substituted heteroarylalkyl group, R4 and R5 are a hydrogen atom or a C1-3 alkyl group. 
Spoj u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da kada je A ravna ili razgranana alkilenska skupina supstituirana skupinom koja je odabrana po izboru od sustituirane aralkilne skupine i po izboru supstituirane heteroarilalkilne skupine, R4 i R5 su vodikov atom ili C1-3 alkilna skupina.
The number of the intra prediction mode groups is 2. 
26.06.2013. Broj objave europskog patenta:
The value of maximum force for the breaking (Fmax), and the value of elongation at break (Ebreak) appeared on the screen of the software is recorded. A method for bonding a first synthetic polymer material to a second synthetic polymer material characterized in that said first and second synthetic polymer materials are moving at a speed of at least 50 meters/minutes and at least a portion of said first synthetic polymer material is pretreated with an atmospheric pressure plasma while it is moving to create a pretreated portion and an adhesive is applied to at least a portion of said pretreated portion, and said pretreated portion is brought into contact with said second synthetic polymer material. 
Metoda za vezivanje prvog poliolefinskog materijala za poliolefinski materijal naznačena time što se spomenuti prvi i drugi poliolefinski materijali kreću brzinom od najmanje 50 m/min i barem dio navedenog prvog poliolefinskog materijala se prethodno tretira plazmom na atmosferskom pritisku dok se kreće kako bi se kreirao prethodno tretirani dio i adheziv se primjenjuje na barem dio navedenog prethodno tretiranog dijela, i navedeni prethodno tretirani dio se dovodi u kontakt sa navedenim drugim poliolefinskim materijalom, pri čemu se navedena metoda primjenjuje za pripremanje dijelova apsorbentnog predmeta za jednokratnu upotrebu odabranog od pelene, higijenskog uloška, pelene na navlačenje, pelene za odrasle, gaćica, dnevnog uloška, i prostirke za jednokratnu upotrebu.
The resulting mixture was extracted with diethyl ether (3×50 mL). 
Dobivenu smjesu ekstrahira se dietil-eterom (3 x 50 ml).
Compounds of formula (XXI) may be prepared by conventional hydrolysis and decarboxylation of a compound of formula (XXII) 
Postupak dobivanja spoja formule (VI), naznačen time što se sastoji u hidrolizi i dekarboksiliranju spoja formule
The method of claim 9, wherein the inducible promoter is a T7 promoter. The method of claim 1, wherein the chromosome of the bacterial host cell comprises a nucleic acid sequence coding for a bacteriophage RNA polymerase, and is free of lysogenic bacteriophage nucleic acid sequences. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što kromosom bakterijske stanice domaćina sadrži nukleinskokiselinski slijed koji kodira RNA polimerazu iz bakteriofaga, operabilno spregnut s lac promotorom, te ne sadrži nukleinskokiselinske sljedove lizogenih bakteriofaga, gdje RNA polimeraza iz bakteriofaga može biti polimeraza T7.
After 30 min, 1-chloro-3-iodopropane (1.6 mL, 15 mmol) was added at once and slowly warmed to room temperature. 
Poslije 30 min., 1-kloro-3-jodopropan (1.6 mL, 15 mmol) je dodan odjednom i lagano zagrijavan do sobne temperature.
The composition for use of claim 1, wherein the polypeptide comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 4. 
Farmaceutski pripravak za uporabu prema patentnom zahtjevu 2, naznačen time što dvolančani polipeptid sadrži aminokiselinsku sekvencu koja ima najmanje 95% homologije sa SEQ ID NO: 13.
One aspect of the present invention pertains to use of a diaminophenothiazinium compound, as described herein, in the manufacture of a medicament for use in the treatment or prophylaxis of a tauopathy condition. 
Farmaceutski sastav, naznačen time, da se upotrebljava u postupku liječenja ili profilakse ljudskog ili životinjskog pojedinca putem terapije, pri čemu taj farmaceutski sastav obuhvaća spoj diaminofenotiazinija koji je odabran od sljedećih:
The examples of the European patent application describe the preparation of a fudge chocolate chip cookie containing partially hydrogenated blend of soybean and palm oil (1:1). 
(97) Broj objave europske prijave patenta: EP 2157865 A1 Datum objave europske prijave patenta: 03.03.2010.
polyester; and poly amide. The intragastric balloon of claim 1, further comprising a removal device attached to the sealed container adapted to communicate the intragastric balloon with the outside environment when the intragastric balloon is passing into the stomach. 
Intragastrički balon (10) sukladno bilo kojem od prethodnih patentnih zahtjeva, koji obuhvaća uređaj (102) za uklanjanje spojen na nepropusno zapečaćeni spremnik prilagođen komunicirati između tog intragastričkog balona s vanjskim okruženjem kada intragastrički balon prolazi u želudac.
% of at least one calcium carbonate-comprising material and having a pH in the range of between 8.5 and 11 is provided, wherein the method involves the step of adding 2-((1-methylpropyl)amino)ethanol to the suspension in an amount, so that the pH of the suspension is increased by at least 0.3 pH units, preferably by at least 0.5 or at least 0.7 pH units and, at the same time, the suspension conductivity change caused by the addition of 2-((1-methylpropyl)amino)ethanol is not more than 100 µS/cm per pH unit, preferably is not more than 50 µS/cm per pH unit and very preferably is not more than 20 µS/cm per pH unit. 
Postupak povećavanja pH vodene suspenzije koja sadrži 25 do 62 vol.% barem jednog materijala s kalcijevim karbonatom i ima pH između 8,5 1 11, naznačen time da postupak uključuje korak dodavanja 2-((1- metilpropil)amino)etanola u suspenziju u količini za povećanje pH otopine za najmanje 0,3 pH jedinice, pri čemu promjena vodljivosti otopine nije veća od 100 uS/em po jedinici pH, naznačen time da je navedeni 2-((1- metilpropil)amino)etanol dodan u navedenu otopinu u količini od 500 do 15000 mg, po litri vodene faze navedene otopine.
A method of treating a condition selected from a group consisting of clinical or pre-clinical Alzheimer's disease, prodromal Alzheimers disease, Down's syndrome, and clinical or pre-clinical amyloid angiopathy (CAA), comprising administering to a human in need thereof the human engineered antibody of claim 4 . A method of treating Alzheimer's disease, comprising administering to a human in need thereof the human engineered antibody of claim 4 . 
Ljudsko modificirano protutijelo, ili njegov antigenski vežući fragment, u skladu s patentnim zahtjevom 1 ili farmaceutski pripravak u skladu s patentnim zahtjevom 2, naznačeno time što je namijenjeno upotrebi u liječenju stanja koje se bira iz skupine koju čine klinička ili pretklinička Alzheimerova bolest, prodromalna Alzheimerova bolest, Down sindrom, te klinička ili pretklinička cerebralna amiloidna angiopatija (CAA), koja se sastoji u primjeni na čovjeku kojem je to potrebno ljudskog modificiranog protutijela u skladu s patentnim zahtjevom 1.
reacting of a compound of formula (II) wherein R1 and R2 are as defined for formula (I) and Q is hydrogen or a suitable nitrogen protecting group with a compound of formula (III) wherein Y and R3 are as defined for formula (I), in reaction conditions suitable for a reductive alkylation, in a suitable solvent; and thereafter optionally carrying out one or more of the following reactions: 
(I) gdje su R! i R* definirani kao za formulu (I), a Q je vodik ili pogodna zaštitna skupina za dušik, sa spojem formule (III) gdje su Y i R definirani kao za formulu (1), u reakcijskim uvjetima pogodnim za reduktivno alkiliranje, u pogodnom otapalu; i b) nakon toga izbornom provođenju jedne ili više naknadnih reakcija:
A packaging according to any of the preceding claims, wherein the inner part is made of plastic, such as transparent plastic or coloured plastic. 
Pakiranje u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time, što je unutarnji dio načinjen od plastike, takve kao što je prozirna plastika ili obojena plastika.
This shows the improved stability of the novel omeprazole salts of the invention. 
Ovo pokazuje povećanu stabilnost novih omeprazol soli iz izuma.
The method of claim 5, wherein the first applicator material exit port is located proximate to the first termination member of the first applicator. 
Postupak iz patentnog zahtjeva 1, naznačen time, da je cjevovod prvog elektromagnetskog aplikatora postavljen horizontalno u odnosu na tlo.
extended-spectrum beta-lactamase (ESBL) producing bacteria. 
- bakterijama koje proizvode B-laktamazu proširenog spektra (ESBL).
R11C and R14C are independently selected from the group consisting of hydrogen, an optionally substituted C1-24 alkyl, an optionally substituted aryl, an optionally substituted -O-C1-24 alkyl and an optionally substituted -O-aryl; 
A i R24A su neovisno odabrani iz skupine koju čine vodik, po izboru supstituiran C1-24 alkil, po izboru supstituiran aril, po izboru supstituiran -O-C1-24 alkil i po izboru supstituiran -O-aril;
The pharmaceutical composition of claim 1, wherein the aqueous buffer provides a pH to the composition of about 6. 
Farmaceutska kompozicija koja sadrži spoj sa formulom (2): i vodeni pufer, gdje kompozicija ima pH od oko 5 do oko 6.
reductive amination of the compound of formula (1) with compound of formula (2) in presence of a suitable solvent and reducing agent to form a compound of formula (I), wherein all substitutions are as defined in claim 1, optionally converting the compound of formula (I) to their pharmaceutically acceptable salts. 
2 uz prisutnost pogodnoga rastvarača 1 reduktirajućeg agensa da se formira spoj iz formule (1), pri čemu sve supstitucije kako je definirano u patentnom zahtjevu 1, (b) - opciono pretvaraju spoj iz formule (1) u njihove farmaceutski prihvatljive soli.
is fused to another peptide or polypeptide sequence such as a linker, an activating molecule or a toxin; or 
(i) fuzioniran s drugim peptidnim ili polipeptidnim slijedom, poput spojnice, aktivirajuće molekule ili toksina; ili
an inverter capable of servo-locking said inverter motor; 
inverter (52a) koji može servo-zaključati taj inverter motor;